Medifast, Inc. (MED) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Medifast, Inc. operates the OPTA VIA lifestyle solution, a coach-guided weight management program. The company is currently executing a business transformation to adapt to the rapid market adoption of GLP-1 weight loss medications. As of June 30, 2025, the company had approximately 22,800 active earning coaches, a significant decrease from 33,900 in the prior year.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $105.6M | $168.6M | $221.3M | $343.3M |
| Gross Profit | $76.6M | $123.4M | $160.9M | $250.7M |
| Gross Margin | 72.6% | 73.2% | 72.7% | 73.0% |
| Operating Income (Loss) | ($1.1M) | ($7.9M) | ($2.3M) | $0.1M |
| Net Income (Loss) | $2.5M | ($8.2M) | $1.7M | $0.2M |
| Diluted EPS | $0.22 | ($0.75) | $0.15 | $0.01 |
| Cash & Equivalents | $101.7M | $90.9M (Dec '24) | Investments: $61.0M | |
| Working Capital | $160.3M | $150.2M (Dec '24) | Debt: $0 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 37.4% in Q2 and 35.5% year-to-date compared to 2024. This is primarily driven by a 32.7% drop in active earning coaches and a 6.9% decline in revenue per coach.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses fell 40.8% in Q2. This reduction was driven by lower coach compensation and the absence of one-time costs incurred in Q2 2024, including $12.5M for supply chain optimization, $3.0M for convention cancellation, and $2.0M for LifeMD collaboration.
- Investment Gain: The company recorded a $2.6M gain in Q2 2025 from the sale of its entire investment in LifeMD, Inc. (LFMD). This contrasts with a $4.2M loss on the same investment in Q2 2024.
- Operating Performance: Despite lower revenue, the operating loss narrowed significantly from $7.9M in Q2 2024 to $1.1M in Q2 2025 due to aggressive cost management.
Outlook, Risks, and Management Commentary
- GLP-1 Strategy: Management acknowledges GLP-1 medications as a major competitor but positions OPTA VIA as a complementary lifestyle solution. The company offers three distinct program tracks: non-medication, GLP-1 supported, and post-GLP-1 maintenance.
- Coach Initiatives: New programs like "EDGE" and "Premier+" (launched July 2025) aim to improve coach retention and client acquisition through better incentives and pricing structures.
- Liquidity: The company maintains a strong balance sheet with $162.7M in cash and investments. It terminated its credit facility in October 2024 and currently has no debt.
- Risks: Key risks include continued decline in coach numbers, macroeconomic inflation/tariffs affecting raw material costs, and the ongoing shift in consumer preference toward pharmaceutical weight loss solutions.
- Tax Legislation: A subsequent event noted the enactment of the "One Big Beautiful Bill Act" (OBBBA) on July 4, 2025, which may impact the timing of tax deductions for R&D and fixed assets, though the effective tax rate is not expected to change materially.
Investor Verification Checklist
- Coach Churn: Verify the sustainability of the 32.7% year-over-year decline in active earning coaches and the effectiveness of new retention programs.
- Revenue Per Coach: Monitor the trend of revenue per active coach, which has been declining since Q3 2022.
- One-Time Costs: Confirm that SG&A expenses in future quarters do not include recurring costs that were previously classified as one-time (e.g., supply chain optimization).
- LifeMD Collaboration: Assess the ongoing revenue impact of the LifeMD collaboration now that the equity investment has been sold.
- Cash Flow: Review operating cash flow, which dropped to near zero ($28k) for the six months ended June 30, 2025, compared to $20.4M in the prior year period.